Announcement of Granted Patent – World’s first substance patent for human LPA1

We are pleased to announce that the substance patent for a functional antibody that specifically recognizes human LPA1 and has inverse agonist activity, for which we have applied, has been granted and published in the Japanese Patent Office.

This is the first time in the world that a substance patent has been granted for a functional antibody against this target.

This technology has also been shown to bind specifically to mouse LPA1 and exhibit inverse agonist activity as well, which will accelerate the development of LPA1 as a therapeutic agent for fibrosis and other diseases targeting LPA1.

  • Patent No.: Patent No. 7569045 (P7569045)
  • Publication number:WO/2024/085081
  • Registration date: October 8, 2024
  • Title of the Invention:ANTIBODY, NUCLEIC ACID, CELL, AND PHARMACEUTICAL